The Food and Drug Administration is reviewing a first-of-its-kind application from HRA Pharma for Opill. If green-lit by the agency, Opill would become the first daily, hormonal birth control pill sold without a prescription, or over the counter. The submission of the application follows more than six years of studies the company has run. Alice Miranda Ollstein reports.
